
Triumvira Immunologics
@triumvirainc
ID: 1604898607936708608
19-12-2022 17:57:06
182 Tweet
60 Takipçi
19 Takip Edilen

🧬Breaking: Triumvira Immunologics sharing TACTIC-3 trial data at #SITC2024! Dr. Ecaterina Dumbrava of MD Anderson Cancer Center presents TAC101-CLDN18.2 solid tumor therapy results Nov 8. #CellTherapy #CancerResearch #Oncology


Excited to share! Our President & COO Robert Williamson sat down with @Rahulc on the Biotech2050 Podcast to talk career journey, leadership at Triumvira Immunologics, and his driving passion for developing life-changing therapeutics 🎙️ Check it out: bit.ly/3YRJ6Z9 #CellTherapy


Honored that our late-breaking abstract on TACTIC-3 was selected for oral presentation at #SITC2024! Thank you Society for Immunotherapy of Cancer for this opportunity and Dr. Ecaterina Dumbrava of MD Anderson Cancer Center for presenting our promising data! Check it out: prn.to/4fKedLB #SITC2024


More exciting news from #SITC2024! MD Anderson Cancer Center featured our oral presentation on TAC01-CLDN18.2's safety & promising clinical activity in Claudin 18.2+ solid tumors in their SITC Special Edition. Read more: bit.ly/48VDU9Z #Immunotherapy #CellTherapy #CancerResearch


What an incredible turnout at #SITC2024! Thank you to everyone who attended our presentation, to Dr. Dumbrava for delivering it brilliantly, and to Society for Immunotherapy of Cancer for a fantastic event! #CellTherapy #CancerResearch


💜 November is #StomachCancer Awareness Month Triumvira Immunologics is advancing breakthrough cell therapies targeting Claudin 18.2+ tumors to help gastric cancer patients. Together, we're bringing new hope to patients and their families. #GastricCancer #CellTherapy



Check out this infographic illustrating the latest gastric cancer statistics from American Cancer Society Awareness, early detection, and prompt treatment are critical. #CancerAwareness #CellTherapy




Triumvira Immunologics is advancing cancer cell therapy on two fronts: personalized treatments using patients’ own immune cells and ‘off-the-shelf' therapies. #Immunotherapy #CellTherapy #CancerResearch


Excited to share that clinical data from our TACTIC-3 trial will be presented at the 2025 #ASCO GI Symposium by Dr. Ecaterina Dumbrava of MD Anderson Cancer Center See the following link for additional details: bit.ly/4hnCNTn #Immunotherapy #CellTherapy #CancerResearch





Triumvira Immunologics will be presenting updated clinical data at the Society for Immunotherapy of Cancer Spring Conference. Learn more here: prn.to/3DLV7Yb #Immunotherapy #CellTherapy #CancerResearch


Triumvira Immunologics Chief Technology Officer, Donna Rill, delivered a thought-provoking presentation at the 2025 Advanced Therapies Week conference. Check out the full presentation here: bit.ly/4ikxhRy #Immunotherapy #CellTherapy #CancerResearch



